GlobeImmune, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GBIM research report →
Companywww.globeimmune.com
GlobeImmune, Inc. , a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy.
- CEO
- Donald Bellgrau
- IPO
- 2014
- Employees
- 2
- HQ
- Louisville, CO, US
Price Chart
Valuation
- Market Cap
- $575
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 3.84
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 58.99%
- Op Margin
- -42.85%
- Net Margin
- -42.85%
- ROE
- -64.41%
- ROIC
- -38.00%
Growth & Income
- Revenue
- $6.46M · 8.24%
- Net Income
- $-2,766,905 · 86.27%
- EPS
- $-0.48 · 93.05%
- Op Income
- $-2,766,905
- FCF YoY
- 30.74%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -200.46
- Avg Volume
- 609
Get TickerSpark's AI analysis on GBIM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 16, 16 | MITCHELL DANIEL J | sell | 8,862 |
| Mar 17, 16 | MITCHELL DANIEL J | sell | 12,468 |
| Mar 16, 16 | MITCHELL DANIEL J | sell | 112 |
| Mar 17, 16 | MITCHELL DANIEL J | sell | 158 |
| Mar 11, 16 | MITCHELL DANIEL J | sell | 76,662 |
| Mar 15, 16 | MITCHELL DANIEL J | sell | 50,831 |
| Mar 11, 16 | MITCHELL DANIEL J | sell | 2,131 |
| Mar 15, 16 | MITCHELL DANIEL J | sell | 645 |
| Mar 8, 16 | MITCHELL DANIEL J | sell | 5,741 |
| Mar 9, 16 | MITCHELL DANIEL J | sell | 5,643 |
Our GBIM Coverage
We haven't published any research on GBIM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GBIM Report →